临床外科杂志 ›› 2024, Vol. 32 ›› Issue (3): 328-331.doi: 10.3969/j.issn.1005-6483.2024.03.030

• 综述与讲座 • 上一篇    下一篇

免疫检查点抑制剂治疗晚期肝细胞癌的研究进展

周一 梁宾勇 肖震宇   

  1. 430030 武汉,华中科技大学同济医学院附属同济医院肝脏外科
  • 收稿日期:2024-01-23 出版日期:2024-03-20 发布日期:2024-03-20
  • 通讯作者: 肖震宇,Email:xiaozhenyu58@163.com

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma

ZHOU Yi,LIANG Binyong,XIAO Zhenyu   

  1. Hepatic Surgery Center,Tongji Hospital,Tongji Medical College Huazhong University of Science and Technology,Wuhan 430030,China
  • Received:2024-01-23 Online:2024-03-20 Published:2024-03-20

摘要: 肝细胞癌(hepatocellular carcinoma,HCC)是我国常见的恶性肿瘤,起病隐匿,病人就诊时多为中晚期,失去手术机会,预后极差。近年来,以免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)为代表的免疫治疗在晚期HCC治疗中日益普及,但仍有许多病人治疗效果不理想。ICIs与其他治疗的联合方案已成为治疗晚期HCC最有潜力的策略。本文对ICIs单药或联合其他治疗在晚期HCC治疗中的最新研究进展进行综述。

关键词: 晚期肝细胞癌;免疫检查点抑制剂;联合治疗

Abstract: Hepatocellular carcinoma (HCC),frequently diagnosed at advanced stages in China due to insidious onset,faces a dismal prognosis with limited surgical feasibility.The advent of immunotherapy,particularly immune checkpoint inhibitors (ICIs),introduces novel therapeutic prospects,albeit with variable efficacies.The combination of ICIs with various therapeutic strategies is increasingly recognized as a critical approach in the management of advanced HCC.This article reviews recent advances in ICIs for advanced hepatocellular carcinoma and discusses the future prospects of immunotherapy.

Key words: advanced hepatocellular carcinoma; immune checkpoint inhibitors;combination therapy

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!